F. Cornud et al., COLOR DOPPLER-GUIDED PROSTATE BIOPSIES IN 591 PATIENTS WITH AN ELEVATED SERUM PSA LEVEL - IMPACT ON GLEASON SCORE FOR NONPALPABLE LESIONS, Urology, 49(5), 1997, pp. 709-715
Objectives. To compare results of color Doppler-guided ultrasonography
(CDUS) versus those of systematic biopsies in 591 patients with an el
evated serum PSA level and to correlate them with digital rectal exami
nation (DRE) findings. Methods. Biopsies were directed into hypervascu
larized (CDUS+) or hypovascularized (CDUS-) hypoechoic peripheral zone
nodules (443 cases). When transrectal ultrasound (TRUS) was normal (1
48 cases), biopsies were directed into hypervascular areas. Six additi
onal posterior biopsies were also performed in every patient, together
with four anterior biopsies in 117 patients with normal DRE and prost
ate weight above 40g. Results. Biopsies were positive in 339 patients
(57%). Positive biopsy rate (PER) of directed biopsies was 84% in hype
rvascular abnormalities (264 of 316) and 17% in hypovascular nodules (
23 of 134) (P < 0.001). PER of combined biopsies was 84% in CDUS+ pati
ents (266 of 316) and 26% in CDUS- patients (73 of 275) (P < 0.001). C
omparison of TRUS and CDUS showed a sensitivity of 0.9 and 0.78, respe
ctively, and a specificity of 0.46 and 0.8, respectively. Of the 131 p
atients with a PSA level between 4 and 10 ng/mL and a normal DRE, PER
was 59% (22 of 37) when CDUS was positive and 11% (10 of 94) when it w
as negative, regardless of TRUS abnormalities (P < 0.001). Nonpalpable
cancers with a negative CDUS showed a significantly (P < 0.001) lower
Gleason score (5.5 +/- 0.9) than that of CDUS+ cancers (6.5 +/- 1.1).
Eleven cancers were diagnosed by only anterior positive biopsies. All
of them had a negative CDUS and a PSA level above 10 ng/mL. Conclusio
ns. CDUS does not modify prostate biopsy policy except in patients wit
h negative CDUS, normal DRE, and PSA level between 4 and 10 ng/mL, whe
re deferment of biopsy can be advocated. Anterior biopsies are only us
eful in patients with a PSA level above 10 ng/mL and a negative CDUS.
(C) 1997, Elsevier Science Inc.